Literature DB >> 27416776

Co-medication and interference testing in bioanalysis: a European Bioanalysis Forum recommendation.

Marcel de Zwart1, Berthold Lausecker2, Susanne Globig3, Daniel Neddermann4, Bruno Le Bras5, Alberto Guenzi6, Stephen White7, Marianne Scheel-Fjording8, Philip Timmerman9.   

Abstract

Interference testing of co-medication in bioanalytical method validation has become an area of debate in view of the increased specificity offered by current state-of-the-art technology in both LC-MS/MS and ligand-binding assay platforms. In view of this, and considering the extensive experience within the European Bioanalysis Forum member companies, we evaluated the impact of co-medication on the performance of hundreds of bioanalytical methods with the aim of providing a science-based recommendation on how to evaluate and document potential interference from co-medication on the PK parameters in clinical studies in patients and volunteers.

Entities:  

Keywords:  co-medication; interference testing; method validation

Mesh:

Substances:

Year:  2016        PMID: 27416776     DOI: 10.4155/bio-2016-0179

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  2 in total

1.  Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.

Authors:  Susan C Irvin; Amanda D'Orvilliers; Nicolin Bloch; Kayla Boccio; Jason Pennucci; Jurriaan Brouwer-Visser; Erica Ullman; Manoj Rajadhyaksha; Mohamed Hassanein; Terra Potocky; Albert Torri; Aynur Hermann; Michael A Partridge
Journal:  AAPS J       Date:  2022-06-21       Impact factor: 3.603

2.  Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.

Authors:  Andrew F Dengler; Rachel Weiss; Tiffany Truong; Susan C Irvin; Nidhi Gadhia; Mohamed Hassanein; Camille Georgaros; Jessica-Ann Taylor; Anne Paccaly; Giane Sumner; Matthew D Andisik; Albert Torri; Michael A Partridge
Journal:  AAPS J       Date:  2021-10-04       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.